{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:31:22Z","timestamp":1792643482653,"version":"4.5.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,11,15]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>National and international asthma guidelines recommend adjusting asthma treatment based on levels of control, yet no guidance is given regarding the stepping-down of montelukast in children and young people (CYP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically review evidence regarding deprescribing montelukast in CYP with established asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Embase, Medline, PubMed and CINAHL were searched up to October 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection<\/jats:title>\n                    <jats:p>Eligible studies contained patients aged 0\u201318 years with a diagnosis of asthma, who had been administering montelukast before it was withdrawn. All reasons for withdrawal were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search identified 197 papers. After deduplication, five papers were included (three randomised control studies and two cohort studies). Four studies observed the impact of montelukast withdrawal for 2\u2009weeks, and one study for 8\u2009weeks. The impact of withdrawal was measured in the studies using a combination of lung tests (eg, forced expiratory volume in 1 s (FEV1), fractional exhaled nitric oxide (FeNO)), asthma scoring methods and exercise challenges. Of the 17 domains in the Core Outcome Set for Clinical Trials in Childhood Asthma, eight outcomes were measured in at least one of the five studies, with all five studies measuring the outcome of \u2018Lung Function\u2019. No significant differences were found between the montelukast and placebo groups following montelukast withdrawal. Significant differences between the comparator points within the test group were found in nine outcomes across four studies; FEV1\/forced vital capacity, FEV1, forced expiratory flows (25%\u201375%), asthma score (study specific), maximum % fall in FEV1 and time to recovery (post exercise) significantly decreased whereas FEV1\/bronchodilator response, FeNO and eNO significantly increased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Only limited, contradictory and short-term effects of deprescribing montelukast in CYP with established asthma are presented in literature. Definitive studies determining clinical stability, and impact of deprescribing montelukast in CYP are imperative to improve the safety of asthma treatment in CYP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42020213971.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-053112","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T02:57:15Z","timestamp":1643684235000},"page":"e053112","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Deprescribing montelukast in children with asthma: a systematic review"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-0068","authenticated-orcid":false,"given":"Eleanor Grace","family":"Dixon","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool Faculty of Health and Life Sciences, Liverpool, UK"},{"name":"Department of Women\u2019s and Children\u2019s Health, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"King","sequence":"additional","affiliation":[{"name":"Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lilley","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Alder Hey Children's NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian P","family":"Sinha","sequence":"additional","affiliation":[{"name":"Alder Hey Children's NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B","family":"Hawcutt","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, University of Liverpool, Liverpool, UK"},{"name":"Alder Hey Children's Hospital Clinical Research Facility, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"2025121400335845000_12.1.e053112.1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fped.2018.00186","article-title":"The burden of pediatric asthma","volume":"6","author":"Ferrante","year":"2018","journal-title":"Front Pediatr"},{"key":"2025121400335845000_12.1.e053112.2","unstructured":"World Health Organisation . Asthma: World Health Organisation, 2020. Available: https:\/\/www.who.int\/news-room\/q-a-detail\/asthma [Accessed 9 Sep 2020]."},{"key":"2025121400335845000_12.1.e053112.3","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2.3.155"},{"key":"2025121400335845000_12.1.e053112.4","unstructured":"Global Initiative for Athma . Global strategy for asthma management and prevention, 2021."},{"key":"2025121400335845000_12.1.e053112.5","unstructured":"National Asthma Council Australia . Australian asthma handbook, quick reserence guide 2014, 2021. Available: http:\/\/www.trmc.net.au\/pdf\/australian-asthma-handbook.pdf [Accessed 3 Mar 2021]."},{"key":"2025121400335845000_12.1.e053112.6","unstructured":"National Institute for Health and Care Excellence . Asthma: diagnosis, monitoring and chronic asthma management 2017, 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng80\/resources\/asthma-diagnosis-monitoring-and-chronic-asthma-management-pdf-1837687975621 [Accessed 03 Feb 21]."},{"key":"2025121400335845000_12.1.e053112.7","unstructured":"British Thoracic Society and The Scottish Intercollegiate Guidelines Network . SIGN158 British guidelines on the management of asthma [Clinical Guidelines], 2020. Available: https:\/\/www.brit-thoracic.org.uk\/quality-improvement\/guidelines\/asthma\/ [Accessed 9 Sep 2020]."},{"key":"2025121400335845000_12.1.e053112.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025121400335845000_12.1.e053112.9","unstructured":"OpenPrescribing . Montelukast (0303020G0), 2020. Available: https:\/\/openprescribing.net\/chemical\/0303020G0\/ [Accessed 14 Sep 2020]."},{"key":"2025121400335845000_12.1.e053112.10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/164_2016_72","article-title":"Leukotriene receptor antagonists and antiallergy drugs","volume":"237","author":"Tamada","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2025121400335845000_12.1.e053112.11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/ppul.25410","article-title":"Stepping down asthma treatment in children","volume":"56","author":"King","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2025121400335845000_12.1.e053112.12","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-103"},{"key":"2025121400335845000_12.1.e053112.13","unstructured":"Higgins JPT , Jelena Savovi\u0107 MJP , Sterne JAC . The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials 2019, 2021. Available: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials [Accessed 22 Sep 2021]."},{"key":"2025121400335845000_12.1.e053112.14","unstructured":"Wells G , Shea B , O'Connell D . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: the Ottawa Hospital research Institute, 2020. Available: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp [Accessed 8 Dec 2020]."},{"key":"2025121400335845000_12.1.e053112.15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V"},{"key":"2025121400335845000_12.1.e053112.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200x.2005.02142.x"},{"key":"2025121400335845000_12.1.e053112.17","doi-asserted-by":"crossref","unstructured":"Kim J-H , Lee S-Y , Kim H-B . Data from: prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatric Pulmonol 2004.","DOI":"10.1002\/ppul.20156"},{"key":"2025121400335845000_12.1.e053112.18","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/ppul.25085","article-title":"Airway mechanics after withdrawal of a leukotriene receptor antagonist in children with mild persistent asthma: double-blind, randomized, cross-over study","volume":"55","author":"Kim","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2025121400335845000_12.1.e053112.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1587"},{"key":"2025121400335845000_12.1.e053112.20","unstructured":"Nathan RA , Sorkness CA , Kosinski M . Childhood asthma control test for children 4 to 11 years, 2004. Available: https:\/\/www.greenhillspeds.com\/wp-content\/uploads\/2015\/12\/Asthma-Control-Test-4-to-11-years.pdf"},{"key":"2025121400335845000_12.1.e053112.21","unstructured":"U.S. Food and Drug Administration . FDA requires stronger warning about risk of neuropsychiatric events associated with asthma and allergy medication Singulair and generic montelukast, 2020."},{"key":"2025121400335845000_12.1.e053112.22","unstructured":"Mundell EJ . Allergy med singulair to get 'black box' warning over psych side effects: FDA. US News, 2020."},{"key":"2025121400335845000_12.1.e053112.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2021-001206","article-title":"Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review","volume":"5","author":"Dixon","year":"2021","journal-title":"BMJ Paediatr Open"},{"key":"2025121400335845000_12.1.e053112.24","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.00003914"},{"key":"2025121400335845000_12.1.e053112.25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2352-4642(17)30008-1","article-title":"Diagnosis of asthma in symptomatic children based on measures of lung function: an analysis of data from a population-based birth cohort study","volume":"1","author":"Murray","year":"2017","journal-title":"Lancet Child Adolesc Health"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-053112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:34:05Z","timestamp":1765701245000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-053112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,31]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/bmjopen-2021-053112"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-053112","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}